Rapid Complete Response to Single-Agent Bcl-2 Inhibitor Venetoclax in a Heart-Transplanted Patient with Triple Refractory Immunoglobulin Light-Chain Amyloidosis.

Gran, Charlotte; Borg Bruchfeld, Johanna; Ellin, Fredrik; Nahi, Hareth

Gran, Charlotte; Borg Bruchfeld, Johanna; Ellin, Fredrik; Nahi, Hareth.

Affiliation

Gran C; Department of Medicine, Karolinska Institutet, Stockholm, Sweden, charlotte.gran@ki.se.
Borg Bruchfeld J; Department of Clinical Chemistry, Karolinska University Hospital, Stockholm, Sweden, charlotte.gran@ki.se.
Ellin F; Department of Medicine, Karolinska Institutet, Stockholm, Sweden.
Nahi H; Center for Hematology and Regenerative Medicine, Department of Laboratory Medicine, Karolinska Institutet, Stockholm, Sweden.

Acta Haematol ; 143(5): 500-503, 2020.

Article in En | MEDLINE | ID: mdl-31896106

ABSTRACT

ABSTRACT

Immunoglobulin light-chain amyloidosis (AL) is a disease with limited treatment options due to the frailty of patients caused by organ damage. Since the clonal plasma cells often contain the cytogenetic aberration t(11;14), the Bcl-2 inhibitor venetoclax is suggested to have a role in the treatment of AL. Here, we report of a heart-transplanted patient, refractory to multiple therapies, reaching a rapid complete response with single-agent venetoclax.

Subject(s)
Key words

Heart-transplantation; Rapid complete response; Single-agent Bcl-2 inhibitor; Triple refractory immunoglobulin light-chain amyloidosis; Venetoclax

Fulltext

Add to My VHL

XML

PubMed Links

Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Sulfonamides / Bridged Bicyclo Compounds, Heterocyclic / Immunoglobulin Light-chain Amyloidosis / Antineoplastic Agents Type of study: Diagnostic_studies Limits: Female / Humans / Middle aged Language: En Journal: Acta Haematol Year: 2020 Document type: Article

Fulltext

Add to My VHL

XML

PubMed Links

Search on Google